Turna Ray

After the VALID Act didn't pass, it's uncertain how the FDA will proceed, though some payors aren't waiting for the status quo to change and asking labs to submit additional validation data on cancer tests.

During the third quarter, the company saw 24 percent revenue growth from the year-ago period, but the company lowered its full-year expectations.

The company, infamous and long derided in the genetic testing community for refusing to share BRCA1/2 variants, has decided to change its stance as part of a "strategic transformation."

If the Center for Genomic Interpretation's in silico quality assessment catches on with payors, some labs are sure to push back or propose data sharing as an alternative.

The payor wants to see data beyond what is required through CLIA, and recommends labs use the Center for Genomic Interpretation to gauge how well tests detect and interpret variants.

Several institutions, swayed by PGx experts and advocates, are setting up DPYD testing to avoid deadly chemo toxicities in patients even though the NCCN and FDA don't back it. 

Despite the registry's growth in content and utility, currently more than 80 percent of the clinical and genomic data comes from white patients, which AACR wants to change.

The NCI-funded project, which was delayed due to the pandemic, is poised to begin, and aims to provide actionable data and build a reference genome for American Indians.

Data presented at the AACR annual meeting suggests that some recurrent breast cancers after DCIS are actually new primary tumors in some high-risk patients.

The company is offering combined germline and somatic cancer testing, and sharing patients' variants identified through that testing in a new research registry.